Most men with prostate cancer die
of other causes before they ever experience symptoms of the
disease.
Recent studies indicate that patients of
prostate cancer may do about as well in terms of survival by
choosing watchful waiting instead of radical prostatectomy, or
external beam radiation, the standard treatments. So a
question has been raised as to when or if aggressive treatment
is necessary. Watchful waiting is gaining acknowledgment as a
viable first line treatment in some cases of prostate cancer,
particularly when the Gleason Score is low or the patient is
elderly or in otherwise poor health.
|
Exclusive
Presentation on Flash |
 |
|
Anatomy
Of Urinary |
The big news in oncology has been Johnson and Johnson purchasing Cougar Biotechnology for $1 billion. They have just bought promising prostate cancer compound, abiraterone.
So look out for this oral drug.
Dr.Shroff
The data hasn't even been announced at ASCO yet, that's this weekend coming, so one can only speculate that suitors got a sneak peek of the data under an NDA. A billion dollars certainly gets attention and raises the ante for future small oncology biotech deals.